The company specializes in the development of molecular diagnostics technology for early cancer diagnosis, with a focus on identifying and utilizing molecular markers. Their proprietary epigenetic biomarkers enable the detection of cervical precancerous lesions and carcinomas. Using well-established PCR-based technologies, these tests can be performed in routine molecular diagnostics laboratories with standard equipment. By providing screening, therapeutic decision-making, and follow-up care solutions, Oncgnostics aims to offer patients relief and eliminate cancer at an early stage.